Advertisement

The Effect of Hydroxyurea Therapy in Bahraini Sickle Cell Disease Patients

  • Durjoy K. ShomeEmail author
  • Abdulla Al Ajmi
  • Ameera A. Radhi
  • Eman J. Mansoor
  • Kameela S. Majed
Original Article

Abstract

Hydroxyurea (HU) is used as a disease-modifying agent in sickle cell disease (SCD). Its beneficial effects have been ascribed to inhibition of the sickling process through increase of fetal hemoglobin (HbF) levels and influence on multiple factors affecting adhesion of erythrocytes to vascular endothelium. The present study investigates the effect of HU in SCD patients who were grouped on the basis of association with α- and β-thalassemia using routine laboratory methods. A retrospective cross-sectional chart-review was done of 51 adult Bahraini SCD patients attending Salmaniya Medical Complex, Bahrain. Four sub-groups of cases were identified: (i) homozygous sickle cell anemia, 24 cases; (ii) SCD with microcytosis, 16 cases; (iii) sickle α-thalassemia, seven cases; and (iv) sickle β thalassemia, four cases. Documented laboratory and clinical data included hemoglobin level (Hb), hematocrit (Hct), red cell indices, hemoglobin fractions, hospital admissions (frequency), number of inpatient-days, pain episodes (frequency) and red cell transfusion requirement (number of units). Pre- and post-treatment data were compared. Hydroxyurea treatment led to highly significant reduction of HbS % and pain crisis episodes in all patient groups. Other changes such as increases of total hemoglobin, Hct and HbF and reduction of hospital admissions, inpatient days and red cell units transfused also occurred but with less consistent levels of significance within patient sub-groups. Treatment with HU is beneficial for all subgroups of Bahraini SCD patients, without or with α- and β-thalassemia interactions.

Keywords

Sickle cell disease Thalassemia Hydroxyurea Fetal hemoglobin 

Notes

Acknowledgments

The study has been approved by the institutional research ethics committee, Ministry of Health, Kingdom of Bahrain and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Conflict of interest

Authors Durjoy K. Shome, Abdulla Al Ajmi, Ameera A. Radhi, Eman J. Mansoor and Kameela S. Majed declare that they have no conflict of interest.

References

  1. 1.
    Wang WC (2009) Sickle cell anemia and other sickling syndromes. In: Greer JP, Foerster G, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT (eds) Wintrobe’s clinical hematology, 12th edn. Wolters Kluwer, Philadelphia, pp 1038–1082Google Scholar
  2. 2.
    Serjeant GR, Serjeant BE (2001) Pathophysiology of sickle cell disease. Sickle cell disease, 3rd edn. Oxford University Press, Oxford, pp 56–75Google Scholar
  3. 3.
    Fathallah H, Atweh GF (2006) Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Soc Hematol Educ Program 2006:58–62CrossRefGoogle Scholar
  4. 4.
    Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 74:652–656PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 332:1317–1322CrossRefPubMedGoogle Scholar
  6. 6.
    Vichinsky EP (1997) Hydroxyurea in children: present and future. Semin Hematol 34(3 Suppl 3):22–29PubMedGoogle Scholar
  7. 7.
    Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F (1997) Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 89:2554–2559PubMedGoogle Scholar
  8. 8.
    Johnson C, Telen MJ (2008) Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. Haematologica 93:481–485CrossRefPubMedGoogle Scholar
  9. 9.
    Charache S (1997) Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol 34(3 Suppl 3):15–21PubMedGoogle Scholar
  10. 10.
    Mellouli F, Bejaoui M (2008) The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases. Arch Pediatr 15:24–28CrossRefPubMedGoogle Scholar
  11. 11.
    Odièvre MH, Bony V, Benkerrou M et al (2008) Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica 93:502–510CrossRefPubMedGoogle Scholar
  12. 12.
    Halsey C, Roberts IA (2003) The role of hydroxyurea in sickle cell disease. Br J Haematol 120:177–186CrossRefPubMedGoogle Scholar
  13. 13.
    Sheehan VA, Luo Z, Flanagan JM, Howard TA, Thompson BW, Wang WC, Kutlar A, Ware RE, BABY HUG Investigators (2013) Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol 88:571–576CrossRefPubMedGoogle Scholar
  14. 14.
    Hamamy HA, Al-Allawi NAS (2013) Epidemiological profile of common haemoglobinopathies in Arab countries. J Community Genet 4:147–167PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Darbari DS, Onyekwere O, Nouraie M et al (2012) Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr 160:286–290PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Al-Jam’a AH, Al-Dabbous IA (2002) Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia. Saudi Med J 23:277–281PubMedGoogle Scholar
  17. 17.
    El-Hazmi MA, Warsy AS, Al-Momen A, Harakati M (1992) Hydroxyurea for the treatment of sickle cell disease. Acta Haematol 88:170–174CrossRefPubMedGoogle Scholar
  18. 18.
    Fathallah H, Taher A, Bazarbachi A, Atweh GF (2009) Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease. Blood Cells Mol Dis 43:58–62PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    WHO (2011) Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and mineral nutrition information system (WHO/NMH/NHD/MNM/11.1). World Health Organization, Geneva. http://www.who.int/vmnis/indicators/haemoglobin.pdf. Accessed 26 November 2014
  20. 20.
    Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ (1997) Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter study of hydroxyurea. Blood 89:1078–1088PubMedGoogle Scholar
  21. 21.
    Rogers ZR (1997) Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol 34(3 Suppl 3):42–47PubMedGoogle Scholar
  22. 22.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I (2000) Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. Blood Cells Mol Dis 26:453–466CrossRefPubMedGoogle Scholar
  23. 23.
    Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE (2004) Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103:2039–2045CrossRefPubMedGoogle Scholar
  24. 24.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R (2009) Hydroxyurea in sickle cell disease- a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis 42:25–31CrossRefPubMedGoogle Scholar
  25. 25.
    Higgs DR, Aldridge BE, Lamb J, Clegg JB, Weatherall DJ, Hayes RJ, Grandison Y, Lowrie Y, Mason KP, Serjeant BE, Serjeant GR (1982) The interaction of alpha-thalassemia and homozygous sickle-cell disease. N Engl J Med 306:1441–1446CrossRefPubMedGoogle Scholar
  26. 26.
    Vasavda N, Woodley C, Allman M, Drašar E, Awogbade M, Howard J, Thein SL (2012) Effects of co-existing α-thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids. Br J Haematol 157:249–252CrossRefPubMedGoogle Scholar
  27. 27.
    Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99:10–14Google Scholar
  28. 28.
    Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 148:939–955PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S (2008) Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep) 165:1–95Google Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2015

Authors and Affiliations

  • Durjoy K. Shome
    • 1
    • 2
    Email author
  • Abdulla Al Ajmi
    • 3
  • Ameera A. Radhi
    • 2
  • Eman J. Mansoor
    • 2
  • Kameela S. Majed
    • 2
  1. 1.Department of Pathology, College of Medicine and Medical SciencesArabian Gulf UniversityManamaKingdom of Bahrain
  2. 2.Department of PathologySalmaniya Medical ComplexManamaKingdom of Bahrain
  3. 3.Department of Hematology and OncologySalmaniya Medical ComplexManamaKingdom of Bahrain

Personalised recommendations